"We wanted to implement an opioid minimization pathway that was easy to follow and successful,” says Aaron Laviana, MD.
Aaron Laviana, MD, MBA, discusses the background and results of the study, “Decreased opioid use & equivalent pain score outcomes after urologic robotic surgery using a simplified opioid minimization protocol: a prospective, non-inferiority study,” which he presented at the 2022 AUA Annual Meeting (abstract MP31-02)
Laviana Assistant is a professor of Surgery and Perioperative Care at the University of Texas at Austin Dell Medical School.
KIM-1 emerges as biomarker for MRD, atezolizumab benefit in renal cell carcinoma
June 3rd 2024Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma at increased risk of recurrence, according to a retrospective analysis of the phase 3 IMmotion010 trial.